Neuro-Oncology News

NATIONAL HARBOR, Md. — An investigational vaccine of autologous dendritic cells loaded with autologous tumor antigens was safe and feasible as an adjuvant therapy when given after standard care therapies for glioblastoma, according to phase 2 trial results presented at the Society for Immunotherapy of Cancer Annual Meeting.

Plasma cell-free DNA appeared to be an effective biomarker for tumor burden and a viable prognostic tool for disease progression among newly-diagnosed patients with glioblastoma, according to results of a prospective study published in Clinical Cancer Research.

A shortage of the chemotherapy drug vincristine, which is essential to the treatment of most pediatric cancers, has left the oncology community struggling to find short-term solutions while recognizing the need for long-term reform.

Investigators from St. Michael’s Hospital and The Hospital for Sick Children in Toronto have determined that the transcriptional regulatory protein ID1 appears to maintain cancer stem cells in glioblastoma.

Asparagine endopeptidase appeared to promote disease progression among patients with isocitrate dehydrogenase-wild-type glioblastoma by inactivation of p53, according to results of a prospective study published in Journal of the National Cancer Institute.

The FDA awarded 12 grants worth more than $15 million to fund clinical trials of medical products intended to treat patients with rare diseases.

The American Association for Cancer Research today released its annual Cancer Progress Report, which reflects how prior investment in the NIH is paying dividends in terms of advances across the spectrum of cancer care.

BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung Cancer advising all physicians to screen their patients with cancer for tobacco use and recommend tobacco cessation.

A randomized phase 3 trial designed to evaluate the addition of nivolumab to standard therapy for certain patients with newly diagnosed glioblastoma multiforme failed to meet one of its primary endpoints of PFS.

A biology- and response-based treatment algorithm helped reduce therapy for subsets of children with intermediate-risk neuroblastoma while maintaining high rates of 3-year OS, according to results of a prospective phase 3 study published in Journal of Clinical Oncology.